PT-141 (Bremelanotide) Compounding Pharmacy Quality Red Flags to Avoid

What is FDA-approved, and what is not?

Bremelanotide is approved as Vyleesi under NDA 210557, originally approved June 21, 2019, and now held by Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector pen. The label says to inject it into the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. It says more than 8 doses per month is not recommended, and it says to stop after 8 weeks if symptoms have not improved [1].

Products sold as PT-141 or as a research-use peptide are not Vyleesi [1][3]. Apart from the Vyleesi autoinjector there is no FDA-approved bremelanotide product [1]. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness or quality before they are marketed [6].

Red flag: no prescription

Vyleesi is prescription only [1]. A PT-141 listing with no prescription step is a red flag, but that alone does not identify what the product is.

Red flag: uses the label excludes

The label states that Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1]. Marketing that pitches PT-141 for erectile dysfunction, for men, or for postmenopausal women is describing a use the approved product does not cover [1].

What the Vyleesi label warns about

The Vyleesi label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1]. It describes a transient rise in blood pressure after each dose, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after dosing, a heart rate reduction of up to 5 beats per minute, and values usually back to baseline within 12 hours [1]. Focal hyperpigmentation was reported by 1% of patients taking up to 8 doses a month versus none on placebo [1]. Nausea was reported by 40% of Vyleesi patients versus 1.3% on placebo, and 8% stopped the trials because of it [1].

These rates come from the Vyleesi label and should not be treated as established rates for a compounded PT-141 product [1].

Does bremelanotide sit on FDA's safety-risk lists?

No. Bremelanotide does not appear on FDA's page of bulk drug substances that may present significant safety risks (content dated 04/22/2026) or in any category on FDA's bulk-substance lists, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][5][7]. Absence from those lists does not establish that a compounded PT-141 product has been reviewed for safety, effectiveness or quality [6].

Do purity tests and certificates of analysis make a product approved?

No. A purity percentage or certificate provided by a seller is not an FDA approval or review of that product [1][6].

What can you actually check?

• Whether the seller requires a prescription, since Vyleesi is a prescription-only product [1].
• Whether the product is the 1.75 mg Vyleesi autoinjector or something else entirely [1].
• Whether the marketing matches the approved indication [1].
• Whether the seller describes the product as a compounded or research-use peptide rather than the approved autoinjector [1][3].